Project Grant R01HL188381
Award Date 8/7/26
Completion Date 5/31/31
Dollars Obligated $803K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $624,789 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop prenatal diagnosis methods for coarctation of the aorta using cardiac magnetic resonance imaging. The project addresses the high false positive rate of fetal echocardiography in detecting coarctation of the aorta, a severe congenital narrowing of the...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $676,602 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of LYVE1-expressing interstitial macrophage-driven vascular remodeling in pulmonary hypertension. The research examines the role of LYVE1+ interstitial macrophages (IMs) in pulmonary hypertension, a deadly, incurable disease of the pulmonary...
- The National Heart Lung and Blood Institute awarded Regents of the University of Michigan $771,350 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an endovascular vortex ultrasound thrombolysis system for treatment of pulmonary embolism. The project will design, fabricate, and characterize a vortex ultrasound transducer integrated into a 9-French catheter to achieve rapid (under 30 minutes) and safe thrombolysis with minimal lytic agent and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $1,357,964 on August 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to discover prognostic biomarkers of early pulmonary fibrosis and develop secondary prevention strategies. The research identifies genetic, molecular, and environmental biomarkers that trigger and predict progression of fibrotic interstitial lung abnormalities (FILAs)...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $593,985 on September 15, 2025, under Cardiovascular Diseases Research (CFDA 93.837) to develop artificial intelligence techniques that convert photoplethysmography measurements from off-the-shelf wearable devices into multi-lead electrocardiogram signals for real-time evaluation of acute myocardial infarction outside clinical settings. The project addresses a clinical gap: while electrocardiography is the gold...
- The National Heart, Lung, and Blood Institute of the National Institutes of Health awarded St. John's University, New York, $562,500 under the Cardiovascular Diseases Research program on July 15, 2026, to develop RESPOND, a hybrid neuro-symbolic artificial intelligence system designed to identify FDA-approved drugs suitable for repurposing as treatments for pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The award funds research using novel AI tools to analyze biomedical...
- The National Heart Lung and Blood Institute awarded Case Western Reserve University $1,573,126 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence-based decision-support tool that identifies patients at risk of myocardial ischemia using low-cost or no-cost screening data. The tool will analyze CT calcium scores, electrocardiogram data, and clinical risk factors to serve as a gatekeeper strategy for determining which patients...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $746,392 in project grant funding on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to delineate ventilator-induced lung injury arising from specific types of ventilator dyssynchrony—double-triggered, flow-limited, and ineffective-triggered breaths. The research addresses the gap in understanding dose-response relationships between...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $429,000 Project Grant to the Regents of the University of Michigan on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a rapid, non-contrast, low-field magnetic resonance imaging (MRI) pipeline for detecting pulmonary embolism (PE). The project, which extends through July 31, 2027, focuses on creating an efficient 3D, contrast-free MRI protocol utilizing...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $163,285 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year career development project studying the intersection of cardiovascular disease and cancer. The award funds research investigating how colon cancer mediates arterial remodeling through smooth muscle cell phenotypic changes via PDGFR-B signaling. The project...